View in EDS HTML Full Text PDF Full Text

Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study: NUN-004 in Patients with Amyotrophic Lateral Sclerosis: M. Gerometta et al

Saved in:
Bibliographic Details
Title: Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study: NUN-004 in Patients with Amyotrophic Lateral Sclerosis: M. Gerometta et al
Authors: Gerometta, Michael1 (AUTHOR) mike@biosensisconsulting.com, Henderson, Robert D.2 (AUTHOR), Friend, Richard3 (AUTHOR), Cooper, Leanne T.1 (AUTHOR), Zhao, Jing1 (AUTHOR), Boyd, Andrew W.4 (AUTHOR), Bartlett, Perry F.1 (AUTHOR)
Source: Clinical Drug Investigation. Jan2025, Vol. 45 Issue 1, p17-28.
Database: SPORTDiscus with Full Text
Full text is not displayed to guests.
Description
ISSN:11732563
DOI:10.1007/s40261-024-01410-x